The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
14
Intravenous infusion 100 mg/ml
Mayo Clinic Minnesota
Rochester, Minnesota, United States
RECRUITINGAlternative Complement Pathway Biomarkers at time of delivery
Concentration in serum of biomarkers: sMAC, Bb, and C5 at time of delivery
Time frame: Baseline
Pregnancy duration
Length of pregnancy measured in number of weeks.
Time frame: Approximately 40 weeks
Clinical biomarkers of severe features of preeclampsia and HELLP syndrome
Concentration of clinical biomarkers in serum: creatinine, AST, ALT, LDH and platelets
Time frame: 72 hours after Ravulizumab infusion
Hospitalization length in the postpartum period
Length of hospital stay measured in number of days in hospital stay (peripartum period)
Time frame: Approximately 3-5 days, it may vary
Meningococcal infection after use of ravulizumab
Number of participants to present a meningococcal infection after use of Ravulizumab
Time frame: 72 hours up to 3 weeks after Ravulizumab infusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.